KALARIS THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable
KALARIS THERAPEUTICS, INC. (KLRS) reported Increase (Decrease) in Accounts Payable of -$232.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $144.00K, a 88.97% decline year-over-year.
- KALARIS THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$376.00K, a 140.26% decline year-over-year.
- KALARIS THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $874.00K.
- KALARIS THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$3.20M, a 288.02% decline year-over-year.
- KALARIS THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2025 was -$88.00K.
- KALARIS THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2024 was -$1.03M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $144.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$232.00K 10-Q · filed 2026-08-11 | $642.00K derived: sum of 3 quarters · filed 2026-08-11 | -$2.56M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$376.00K 10-Q · filed 2026-05-12 | $498.00K derived: sum of 2 quarters · filed 2026-05-12 | -$2.70M derived: sum of 3 quarters · filed 2026-05-12 | -$1.40M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $874.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$2.33M derived: sum of 2 quarters · filed 2026-03-17 | -$1.02M derived: sum of 3 quarters · filed 2026-08-11 | -$88.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | -$3.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.90M derived: sum of 2 quarters · filed 2026-08-11 | -$962.00K 10-Q · filed 2025-11-12 | -$1.86M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $2.24M 10-Q · filed 2026-08-11 | $1.34M derived: sum of 3 quarters · filed 2026-08-11 | $3.04M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $934.00K 10-Q · filed 2026-05-12 | $36.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.74M derived: sum of 3 quarters · filed 2026-05-12 | $1.14M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$898.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $805.00K derived: sum of 2 quarters · filed 2026-03-17 | $208.00K derived: sum of 3 quarters · filed 2026-03-17 | -$1.03M 10-K · filed 2026-03-17 |
| 2024-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.11M derived: sum of 2 quarters · filed 2025-11-12 | -$129.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$597.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$1.83M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | -$1.24M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |